The therapy combines low-dose interleukin-2 and CTLA-4 Ig, intended for subcutaneous administration in ALS patients.

Current therapies for gMG include AstraZeneca/Alexion's complement C5 inhibitor Ultomiris (ravulizumab), which needs to be ...

Company to present topline 40-week Phase 2 study efficacy and safety results of migaldendranib (MGB), a novel first-in-class nanomedicine for DME ...

Cemdisiran is a subcutaneously-administered, small interfering RNA therapeutic that reduces the production of complement factor 5 in the liver.

Cemdisiran monotherapy, dosed subcutaneously every three months, met the primary and key secondary endpoints, showing a 2.3-point ...

Researchers investigated the long-term of safety and efficacy of subcutaneously injected pertuzumab and trastuzumab in patients with HER2-positive early breast cancer.

The Food and Drug Administration approved Papzimeos (zopapogene imadenovec-drba) for the treatment of adults with recurrent ...